RankAlpha logo
Back to Rankings

AKAN

AkandaC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The constructive read is that Akanda already cured one Nasdaq issue by filing its delayed 20-F, showing it can at least address procedural compliance items, and a submitted equity-remediation plan could buy time for restructuring or capital actions [#PR-2026-06-12] [#PR-2026-06-18].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -16.5.
What can break
Low-coverage evidence set: no analyst targets, no earnings packet, no insider packet, and no direct operating peers in the provided materials.
Momentum
78
Value
41
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.50 · Bull $14.00 · Bear $5.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Why
Momentum78 · Δ7d -16.5
Value41 · Δ7d -0.1
Sentiment46 · Δ7d +21.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
78
26% active weight
Current posture
7d trendFlat
Δ7d
-16.5
Δ21d
-21.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
46
34% active weight
Current posture
7d trendImproving
Δ7d
+21.9
Δ21d
+14.1
Why this grade

Composite grade C. Momentum 78.2 / Value 41.1 / Sentiment 46.1

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$7.22M
Beta
1.69
Shares Out
785.66K
P/E (TTM)
0.2
P/S (TTM)
0.47
P/FCF (TTM) · Derived
-0.10
Rev YoY
+21.9%
EPS YoY
+86.6%
Gross Margin
-383.7%
Op Margin
-366.6%
Net Debt
$10.21M
Current Ratio
0.58
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology